Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PPHM news out this morning.
PR: 2-27-06: Initial Safety Results of Tarvacin HepC Trial
“Clinical Trial Results Show that Peregrine's First-In-Class Anti-Viral Agent Tarvacin is Safe and Well-Tolerated in HCV Patients - First Human Data Demonstrating the Safety of Tarvacin Will Be Presented Today at the 2nd Annual 'Viral Hepatitis in Drug Discovery and Development' Conference”
http://www.peregrineinc.com/content.php?mi=MTc=&appAction=--PRINT&Id=ODIyMTk0
BOSTON & TUSTIN: Feb. 27 2005: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it will present top line data demonstrating that its first-in-class anti-viral compound Tarvacin Anti-Viral appeared safe and well-tolerated in a Phase l study in chronic Hepatitis C virus (HCV) infected patients. Initial results from the Phase l study will be presented at 1:50 pm EST today at the Strategic Research Institute's 2nd Annual "Viral Hepatitis in Drug Discovery and Development" conference in Boston.
Tarvacin Anti-Viral is the first in a new class of anti-phosphotidylserine (PS) immunotherapeutics that targets and binds to cellular components that are normally not present on the outside of cells, but which become exposed on certain virally infected cells and on the surface of enveloped viruses. Tarvacin helps stimulate the body's immune defenses to destroy both the virus particles and the infected cells.
The primary goals of the Phase l study were to determine the safety profile and distribution properties of Tarvacin in patients with chronic Hepatitis C viral infections. The data will support initiation of repeat dose and combination therapy trials that the company expects to begin later this year. In the ascending, single dose trial, 24 patients with chronic HCV who had either failed or who no longer responded to standard-of-care treatment were administered Tarvacin Anti-Viral. The drug was well tolerated, with no serious adverse events reported at any of the 4 dose levels tested, and no potential dose limiting toxicities were observed. Reported adverse events were mild, infrequent, transient and likely not drug-related.
"Demonstrating the safety of the new approach is a critical step in developing a first-in-class therapeutic, so this Phase l data indicating that Tarvacin appears to be safe and well-tolerated is a key milestone for the program," said Steven W. King, CEO of Peregrine. "Completing this study ahead of schedule with the safety profile observed should help us to expedite advancing the Tarvacin Anti-Viral HCV clinical program into repeat dose and combination therapy studies this year."
Tarvacin Anti-Viral has shown promise in preclinical studies in a variety of anti-viral and biodefense applications. Anti-PS agents attach to phospholipids found on the surface of virus particles, including HCV, influenza and other virus strains, as well as on the outer surface of human host cells infected with these viruses. Anti-PS immunotherapeutics are believed to work by helping stimulate the body's natural immune defenses to destroy both virus particles and infected cells. The targeted phospholipids are not exposed on healthy cells, which are therefore not affected by anti-PS agents. Since the targeted phospholipids are derived from the host rather than from the virus itself, anti-PS immunotherapeutics are expected to have broad activity against a variety of virus strains and to be less subject to the development of anti-viral drug resistance.
"Tarvacin represents a completely new approach to treating HCV infections, and these initial positive safety data are promising," said Dr. Eliot W. Godofsky, principal investigator of the Phase l study. "While there are a number of new HCV drugs in development, Tarvacin's unique mechanism has the potential to combat the virus in a novel way. In addition, its potential for use in combination regimens to control and ultimately cure HCV warrants further investigation."
Single administration of anti-viral agents is not generally expected to have a significant effect on HCV viral titers as a result of rapid virus production and turnover. However viral titer data are being collected as part of the Tarvacin study design and are currently being analyzed. These data will be discussed in an appropriate future scientific forum along with final safety data from the Phase I trial.
Based on the good safety observed in the highest dose of Tarvacin tested, Peregrine may assess one additional dose level by adding another cohort to the existing HCV study through a protocol amendment. This addition is not expected to affect the timing of the new studies now being planned.
Similar to their anti-viral mechanism, anti-PS immunotherapeutics also bind to phospholipids exposed on tumor blood vessels in all solid cancers tested to date, and they have shown promise in a number of preclinical cancer models. Tarvacin Anti-Cancer is in Phase l clinical trials for the treatment of advanced refractory solid tumor cancers.
About Peregrine:
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and viral diseases. The company is pursuing 3 separate clinical trials in cancer and anti-viral indications with its lead product candidates Tarvacin and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: *snip*
Investors: Brod & Schaffer, 800-987-8256, ir@peregrineinc.com
Media: Stephen Gendel, GendeLLindheim BioCom Partners, 212-918-4650
*end PR*
CKEI seems to be forming a base above .04 as the excitement about their potential brings more and more investors on board. If January numbers come in strong and/or positive news about bio-fuel is released we could be in for a strong rise.
The following key points are from a recent Raging Bull post:
Why You Should Buy Now:
1. 129,776,826 shares OS and 74,296,826 issued
2. 16,000,000 shares bought by insiders
3. CEO holds 34,000,000 of which 15,000,000 are newly acquired
4. December numbers are far greater than their estimates in September
5. Oil price is decreasing causing the spread to increase (more profits)
6. I believe January numbers are going to be 25% higher than Decembers because of the additional clients gained in December and January
7. February will follow suit because of the storm
8. 129,776,826 outstanding shares does not leave very much room for the short houses to work with at these levels of volume days
9. SEC new rules about naked shorts for OTCBB to follow same guidelines as NASDAQ
10. New York State a good possibility to land a big contract with biofuel requirements for all state fuel burning assets.
11. Owners have a long standing and good reps in the industry
12. I have a strong intuition about this company
13. Googling CKEI shows a lot of brokerages paying attention to this stock.
14. The technicals are showing higher lows and higher highs
15. 500,000,000 total shares authorized (this is common and important that this next few months allows CKEI to become less dependent on issuing additional shares)
16. Liabilities in the last 9 months only increased by 222K
17. Assets show to have increased by nearly 1 million
18. Decrease to the Convertible debentures
19. Increase in prepaid expenses by 250K (this is a sign they are starting to become less dependable on outside sources and more on revenue)
20. Over 171,000,000 shares traded in last 7 trading days
21. January numbers due out any day now
22. 50dma crossing 100dma - classic bull run
23. HIGHER HIGHS AND HIGHER LOWS
See source of this information:
Company 10qsb
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3957915
Tarvacin is an exciting product with so much potential - even bird flu! The next few months should be interesting. By the way, the PPHM board has some of the most knowledgeable posters I have ever seen on any board.
CKEI bears watching closely after the 200% rise and subsequent sell-off this week. I am fairly confident we haven't heard the last of the good news that started with the disclosure of the 16 million shares acquired by insiders on 2/7/2006 and was bolstered by the prospect of a 100% rise in revenues for the fiscal year ending 3/30/2006. Possible speculative news about the company's Bio-Heat blended heating oil operation is just one of the possibilities for news. The 77 million shares traded on Monday convinced we there is much interest in this stock and more opportunity to come.
PPHM appears to be gaining momentum again and was up .17 (12%) today. I just can't say enough about the knowledgeable members of the PPHM board here on IH. They provide invaluable information to those interested in this company and it's products.
Flem
CKEI sold off to .038 today with a volume of over 48 MILLION shares. That followed Monday's 77 MILLION shares and a meteoric rise from .025 to .072. The 10Q released late Monday had some scary elements but revenue is increasing sharply and the company's concept is compelling. I have a feeling the quarterly report had less to do with today's decline than the profit taking after a 200% climb on Monday. The insider buying on 2/7/06 looms large on this stock's horizon and I expect we will hear more good news soon.
Flem
I feel better just knowing I am not completely alone. Good to hear from you.
Step one: unexpected and really positive news, Step two: unpleasant but necessary news, Step three: very positive but speculative news. I believe we are about to see step three.
Flem
Even though I seem to be talking to myself, I am going to post something anyway. We have the first two quarters behind us and still no hint of pending profitability. I am hoping this will be a case of getting all the negative stuff out of the way so the impending good news will have a greater impact. It couldn't hurt to see some insider buying on the open market just to kick things off.
EKCS second quarter 10Q due out this week. This fiscal year has been projected to be profitable and the second quarter numbers may be the first indication of that potential. EKCS has some very impressive customers for such a small company.
Flem
Should be an interesting week with the 10Q due.
Status hearing 2/17/2006, Judge Peter Breen, Second Judicial District Court, Washoe County, Nevada, 1:30 PM. Case CV05-00465.
PPHM now down .07 but given the volatility it has exhibited this week, this could be another opportunity to get in at a very attractive level. Another PR like the Tarvacin news on January 18 would probably send the price back to new highs.
Flem
PPHM looks interesting this week after the Tarvacin news on January 18. The sell-off on Monday presented a nice re-entry point for those who sold during the run-up to 1.76. The PPHM board has some very knowledgeable posters for anyone who would like to know more about the potential of the company's products.
Flem
PPHM recovering nicely after sell-off on Monday. The PPHM board has a wealth of very impressive information about the potential of this company's products. I was able to pick up more shares at 1.35 on Tuesday and plan to continue buying at anything below 1.50.
Flem
Mick, PPHM had an impressive week and it doesn't appear to be through. The guys on the PPHM board here at IH impress me as some of the most knowledgeable of any board I have ever read. The sentiment there is very positive.
Flem
I am encouraged that there is little selling at the current level of 1.08 - 1.10. Hopefully, all the "free" shares are gone and the smart money is waiting for a rise in the price as we approach the quarterly report. A few good news releases wouldn't hurt either. Good luck to all.
Flem
I certainly hope you are right and I am fairly confident that the stock has the potential to go to $3.00 or more, assuming the company executes well.
The Debentures have a term of three years and come fully due on January 11, 2009. The Debentures are convertible at the option of the holder at any time and from time to time into shares of common stock of ECSI at a conversion price of $1.15 per share of common stock, or initially 869,566 shares of common stock, subject to certain adjustments. In the event that ECSI issues common stock in an equity financing at a price less than the then conversion price, the conversion price shall be immediately adjusted to the price at which such common stock was issued, subject to certain exempt issuances.
Okay, so the bottom line is that the holders of the debentures get 869,566 shares up front at no more than $1.15 and they will very likely sell them as fast as they can. Our best hope will be that the company will soon report new contracts and a profitable second quarter which will allow the debenture holders to recoup their money quickly. Otherwise, I think it may be another disappointing year for us small investors.
World Water and Power (WWAT) is up this morning with increased volume. This one may have some legs!
World Water and Power (WWAT) up this morning with increased volume. We may be seeing the start of a significant move.
I wonder if the small amount of selling going on now is coming from the promotional payments to the stock hype website? I assume they want to cash in as soon as possible and with a basis of zero they probably would not be hesitant to sell at these levels. I am thinking we will have all this low price selling behind us soon.
I feel very good for both of us and for anyone who bought during the year end tax loss selling. Hopefully, this will be a big year for EKCS and all patient shareholders.
Lower than .88?
I was shocked at how cheaply I was able to buy shares in the last few days of 2005. In any case, I think we have seen the last of the shares below one dollar. Let's hope the company can now move on to profitability and that target price of $3.00.
I think we can expect to stay in this low range until the first of January after the tax loss selling is over. I am expecting the price to move up quickly to the 1.30 - 1.50 range in 2006. Merry Christmas to all.
World Water and Power Corp.(WWAT) news. I am predicting this one will do well after a difficult current quarter, and I am a buyer here.
WorldWater & Power Corp. Signs $1.145 Million Contract to Provide Solar Power for California Embroidery Plant
Wednesday December 21, 7:30 am ET
With New Contract, Company Announces Revenue Guidance for 2006
PENNINGTON, N.J.--(BUSINESS WIRE)--Dec. 21, 2005--WorldWater & Power Corp. (OTC BB: WWAT - News), developer of proprietary high-powered solar energy systems, today announced that it has signed a $1,145,800 contract to build and install a solar electric power generation system for Quality Embroidery in Los Angeles, California. The photovoltaic (PV) system will provide electricity for the company, and is expected to substantially reduce electrical usage costs for the facility.
With the signing of this contract, on top of its earlier announced 2005 contract backlog of $23 million, the Company issued Revenue Guidance for 2006, projecting Revenue of $25 million to $35 million.
For Quality Embroidery, WorldWater & Power Corp. plans rooftop and carport installation of the PV panels that will power the system. Plans call for construction of the carport and installation of the systems by GJ Electric of Los Angeles. The project will be managed and supervised by Quantum Energy Group, the California engineering, construction and project management firm acquired by WorldWater & Power Corp. earlier this year. The contract is subject to approval of financing and the utility rebate application, following which construction is expected to begin immediately.
About WorldWater & Power Corporation
WorldWater & Power Corporation is a full-service, international solar engineering and water management company with unique, high-powered and patented solar technology that provides solutions to a broad spectrum of the world's water supply and energy problems. For more information about WorldWater & Power Corp., visit their website at www.worldwater.com.
Information about WorldWater's newly acquired subsidiary, Quantum Energy Group, is available at www.quantumenergygroup.com.
Forward Looking Statement
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's 10-KSB and its quarterly reports on Form 10-QSB both as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.
Contact:
WorldWater & Power Corp.
Rose Mary Schwarz, 609-818-0700, ext. 33
rschwarz@worldwater.com
--------------------------------------------------------------------------------
Source: WorldWater & Power Corp.
This news seems to validate the long term value of this stock even though the current quarter may not be all that impressive. I'm definitely a buyer here.
WorldWater & Power Corp. Signs $1.145 Million Contract to Provide Solar Power for California Embroidery Plant
Wednesday December 21, 7:30 am ET
With New Contract, Company Announces Revenue Guidance for 2006
PENNINGTON, N.J.--(BUSINESS WIRE)--Dec. 21, 2005--WorldWater & Power Corp. (OTC BB: WWAT - News), developer of proprietary high-powered solar energy systems, today announced that it has signed a $1,145,800 contract to build and install a solar electric power generation system for Quality Embroidery in Los Angeles, California. The photovoltaic (PV) system will provide electricity for the company, and is expected to substantially reduce electrical usage costs for the facility.
With the signing of this contract, on top of its earlier announced 2005 contract backlog of $23 million, the Company issued Revenue Guidance for 2006, projecting Revenue of $25 million to $35 million.
For Quality Embroidery, WorldWater & Power Corp. plans rooftop and carport installation of the PV panels that will power the system. Plans call for construction of the carport and installation of the systems by GJ Electric of Los Angeles. The project will be managed and supervised by Quantum Energy Group, the California engineering, construction and project management firm acquired by WorldWater & Power Corp. earlier this year. The contract is subject to approval of financing and the utility rebate application, following which construction is expected to begin immediately.
About WorldWater & Power Corporation
WorldWater & Power Corporation is a full-service, international solar engineering and water management company with unique, high-powered and patented solar technology that provides solutions to a broad spectrum of the world's water supply and energy problems. For more information about WorldWater & Power Corp., visit their website at www.worldwater.com.
Information about WorldWater's newly acquired subsidiary, Quantum Energy Group, is available at www.quantumenergygroup.com.
Forward Looking Statement
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's 10-KSB and its quarterly reports on Form 10-QSB both as filed with the Securities and Exchange Commission, which include the Company's cash flow difficulties, dependence on significant customers, and rapid development of technology, among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.
Contact:
WorldWater & Power Corp.
Rose Mary Schwarz, 609-818-0700, ext. 33
rschwarz@worldwater.com
--------------------------------------------------------------------------------
Source: WorldWater & Power Corp.
Important SEC filing for fpfx. http://www.secinfo.com/$/SEC/Filing.asp?D=1526c.z1N7&CIK=1333612
Does anyone have any comments on this stocklemon report? http://www.stocklemon.com/08_25_05.html
I think there may be just two issues keeping us from breaking out to new highs and those are (1) profitability and (2) the age of the CEO. While the second is probably not nearly as significant as the first, I do hope it is addressed at the annual meeting. The news on Wednesday further supports the likelihood of near term profitability and if the issue about Barchenko's age is addressed at the meeting this month, I think we may be in for a nice Christmas present.
Thanks again! Your suggestions are proving most helpful in developing a board about this company. I have a lot to learn about this company, but have been favorably impressed so far.
Thanks for the information! I am delighted to hear from someone who has already invested in the company. I think I understand the risks associated with insuring property and casualty in a hurricane prone area, but I am guessing UVIH has a plan to make money and the trick for investors is to determine just how sound that plan is. I was attracted to this company because they seem to be somewhat successful at what they are doing at a time when some of the bigger companies may be wanting out. Am I correct that the Florida Residential Property and Casualty Joint Underwriting Association ("JUA") is the state agency that assumes the policies of failed insurers? If IVIH can take the premiums and minimize the risk with good underwriting practices and reinsurance then they should be able to make money and grow at the same time. Of course, the very idea of insuring property and casualty in Florida is a scary prospect for investors, but isn't that the very reason that the share price is at .62 instead of 2.00? I mean it is risky, but if it wasn't we wouldn't be talking about getting in at such a low pe. As for an entry point, I think I will wait for something under .50 since there was a very recent run up and the trading volume is relatively low.
I came across this company by chance but it looks very interesting. If I understand it correctly, and I may not, they are taking advantage of some new laws and/or regulations in Florida established after hurricane Andrew. I still have much DD to do but I wanted to get started and invite others to join me, before deciding whether to invest or not. If you are knowledgeable about this company or the business in general, I encourage you to join this discussion board.
I tried to buy shares below one dollar today and, wouldn't you know it, the share price goes up 14%. Where is the justice?
EKCS is back on the SHO Threshold List again! I just can't help wondering if naked shorting is part of the reason for the low share price. Of course the continued losses with the increased revenues didn't help, but profitability seems close - very likely this year. I suppose I should be happy to pick up the cheap shares!
EKCS traded down for most of the day Wednesday, then up significantly right at the close as if someone wanted to scoop up any shares shaken loose during the day. The first quarter report is due out in the next few days and I am hopeful revenues will be up due to acceleration of existing contracts.
Good morning everyone. EKCS had an interesting day yesterday trading down for most of the day, then up significantly right at the close as if someone intended to scoop up any shares shaken loose during the day. The quarterly report should be out next week and I am hopeful that revenues will be up dramatically over last year due to the acceleration of existing contracts.
Interesting trading Wednesday, moving higher right at the close. It was as if someone wanted to scoop up anything shaken loose during a basically down day. Hopefully, this portends better things to come.
I hope the quarterly report puts an end to this selling below 1.25!